Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896269 | 1.00 | CTSC (0.41) | CTSCRNPEPANPEPMETAP2METAP1 | |
| SCHEMBL3686360 | 1.00 | CTSC (0.41) | CTSCRNPEPANPEPMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL3458429 | 0.98 | CTSC (0.40) | CTSCRNPEPANPEPMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL2253202 | 0.98 | CTSC (0.40) | CTSCRNPEPANPEPMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL3458427 | 0.98 | CTSC (0.40) | CTSCRNPEPANPEPMETAP2METAP1 | |
| SCHEMBL19380208 | 0.88 | NOS3 (0.41) | ANPEPMETAP2METAP1HDAC7HDAC8 | |
| Norvaline SCHEMBL4543134 | 0.87 | NOS3 (0.42) | RNPEPHDAC7HDAC8HDAC6HDAC9 | |
| SCHEMBL17746783 | 0.85 | SLC15A1 (0.48) | CTSCRNPEPANPEPMETAP2METAP1 | |
| SCHEMBL7288155 | 0.83 | CTSC (0.41) | CTSCRNPEPANPEPMETAP2METAP1 | |
| SCHEMBL6690311 | 0.83 | CTSC (0.41) | CTSCRNPEPANPEPMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894525-A | Mucispirillum compositions and methods of treating cancer | 哈佛大学校长及研究员协会 | 2025-04-25 | — | — | CN | disclosed |
| CN-114364267-B | Novel flavor composition, preparation method and application thereof | 国际香料和香精公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230019159-A1 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2023-01-19 | — | — | US | disclosed |
| US-11382328-B2 | Rapid drug discovery methods for pathogen inactivation | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114364267-A | Novel flavor composition, preparation method and application thereof | 国际香料和香精公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20200305423-A1 | RAPID DRUG DISCOVERY METHODS FOR PATHOGEN INACTIVATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104736707-A | Method for producing L-amino acid | AJINOMOTO KK | 2015-06-24 | — | — | CN | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8580859-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-101223280-B | Use of dimethyl disulfide for methionine production in microorganisms | EVONIK DEGUSSA GMBH | 2013-05-15 | — | — | CN | disclosed |
| CN-102171185-A | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICS INC | 2011-08-31 | — | — | CN | disclosed |
| EP-2326619-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | Bioxiness Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| CN-101223280-A | Use of dimethyl disulfide for methionine production in microorganisms | BASF SE (DE) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | CTSC 848/4885RNPEP 261/4885ANPEP 476/4885 |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | CTSC 848/4885RNPEP 261/4885ANPEP 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.